Potential Drug Interactions in Hospitalized Hematologic Cancer Patients: New Update with New Chemotherapy Regimens

Overview

Journal J Res Pharm Pract

Date 2024 Sep 12

PMID 39262411

Authors

Tahereh Gholipourshahraki

Amir Aria

Mehran Sharifi

Ayda Moghadas

Azadeh Moghaddas

Affiliations

Soon will be listed here.

Abstract

Objective: This cross-sectional study aimed to assess the frequency of potential drug-drug interactions (DDIs) and demographic correlates of moderate and major DDIs among patients with hematologic cancer at a referral hematology hospital in Iran.

Methods: In this study, for 6 months, all patients suffering from hematologic cancers admitted to the tertiary oncology hospital, Omid, Isfahan, were considered. Data from all medications prescribed to patients during hospitalization were analyzed using the online Lexicomp drug interaction checker, recording all interactions classified by risk level: C, D, or X.

Findings: A total of 674 DDIs were detected in 109 patients. The prevalence of treatments with at least one clinically relevant interaction was 95%, being 57.9% for those at level C and 31.5% for levels D and X. According to the frequency, the main interaction was between aprepitant and corticosteroids, followed by the interaction between aprepitant and vincristine. The most common interaction between antineoplastic agents was between doxorubicin and cyclophosphamide. In terms of mechanism, most of DDIs (54.9%) were pharmacodynamics. Only the number of administered medications was associated with DDI occurrence.

Conclusion: Potential DDIs of moderate to major severity are common among patients with hematologic malignancies. This underscores the importance of implementing different strategies to mitigate this clinically significant risk.

Citing Articles

Pharmacokinetic Interaction Between Olaparib and Regorafenib in an Animal Model.

Szkutnik-Fiedler D, Karbownik A, Otto F, Maciejewska J, Kuznik A, Grabowski T Pharmaceutics. 2025; 16(12.

PMID: 39771554 PMC: 11678373. DOI: 10.3390/pharmaceutics16121575.

References

Riechelmann R, Moreira F, Smaletz O, Saad E . Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005; 56(3):286-90. DOI: 10.1007/s00280-004-0998-4. View

Song Y, Oh J . Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea. Support Care Cancer. 2019; 28(8):3711-3720. DOI: 10.1007/s00520-019-05221-1. View

Fernandez de Palencia Espinosa M, Diaz Carrasco M, Sanchez Salinas A, De la Rubia Nieto A, Miro A . Potential drug-drug interactions in hospitalised haematological patients. J Oncol Pharm Pract. 2016; 23(6):443-453. DOI: 10.1177/1078155216664201. View

Moreira Reis A, Cassiani S . Evaluation of three brands of drug interaction software for use in intensive care units. Pharm World Sci. 2010; 32(6):822-8. DOI: 10.1007/s11096-010-9445-2. View

van Leeuwen R, Swart E, Boom F, Schuitenmaker M, Hugtenburg J . Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC Cancer. 2010; 10:679. PMC: 3013087. DOI: 10.1186/1471-2407-10-679. View

Hadjibabaie M, Badri S, Ataei S, Moslehi A, Karimzadeh I, Ghavamzadeh A . Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol. 2013; 71(6):1619-27. DOI: 10.1007/s00280-013-2162-5. View

Riu-Viladoms G, Carcelero San Martin E, Martin-Conde M, Creus N . Drug interactions with oral antineoplastic drugs: The role of the pharmacist. Eur J Cancer Care (Engl). 2018; 28(1):e12944. DOI: 10.1111/ecc.12944. View

Guastaldi R, Moreira Reis A, Figueras A, Secoli S . Prevalence of potential drug-drug interactions in bone marrow transplant patients. Int J Clin Pharm. 2011; 33(6):1002-9. DOI: 10.1007/s11096-011-9574-2. View

Riechelmann R, Saad E . A systematic review on drug interactions in oncology. Cancer Invest. 2006; 24(7):704-12. DOI: 10.1080/07357900601063766. View

10.

Riechelmann R, Del Giglio A . Drug interactions in oncology: how common are they?. Ann Oncol. 2009; 20(12):1907-12. DOI: 10.1093/annonc/mdp369. View

11.

Wong C, Ko Y, Chan A . Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother. 2008; 42(12):1737-48. DOI: 10.1345/aph.1L255. View

12.

Riechelmann R, Tannock I, Wang L, Saad E, Taback N, Krzyzanowska M . Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007; 99(8):592-600. DOI: 10.1093/jnci/djk130. View

13.

Diaz-Carrasco M, Almanchel-Rivadeneyra M, Tomas-Luiz A, Pelegrin-Montesinos S, Ramirez-Roig C, Fernandez-Avila J . Observational study of drug-drug interactions in oncological inpatients. Farm Hosp. 2018; 42(1):10-15. DOI: 10.7399/fh.10857. View

14.

Tavousi F, Sadeghi A, Darakhshandeh A, Moghaddas A . Potential Drug-drug Interactions at a Referral Pediatric Oncology Ward in Iran: A Cross-sectional Study. J Pediatr Hematol Oncol. 2018; 41(3):e146-e151. DOI: 10.1097/MPH.0000000000001346. View

15.

Strandell J, Wahlin S . Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database. Eur J Clin Pharmacol. 2011; 67(6):633-41. DOI: 10.1007/s00228-010-0979-y. View

16.

Haidar C, Jeha S . Drug interactions in childhood cancer. Lancet Oncol. 2010; 12(1):92-9. PMC: 4865887. DOI: 10.1016/S1470-2045(10)70105-4. View

17.

Leger D, Moreau S, Signol N, Fargeas J, Picat M, Penot A . Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: Observational single-center study of 122 patients. J Geriatr Oncol. 2017; 9(1):60-67. DOI: 10.1016/j.jgo.2017.07.015. View

18.

Dodion P, Akman S, Tamburini J, Riggs Jr C, COLVIN O, Bachur N . Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system. J Pharmacol Exp Ther. 1986; 237(1):271-4. View

19.

Bibi R, Azhar S, Iqbal A, Jabeen H, Kalsoom U, Iqbal M . Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors. J Oncol Pharm Pract. 2020; 27(7):1616-1622. DOI: 10.1177/1078155220963212. View

20.

Tavakoli-Ardakani M, Kazemian K, Salamzadeh J, Mehdizadeh M . Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country. Iran J Pharm Res. 2013; 12(Suppl):175-82. PMC: 3813358. View